BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28372493)

  • 1. Safety profile of gadoxetate disodium in elderly patients (≥65 years).
    Endrikat J; Schwenke C; Vogtlaender K; Dohannish S; Breuer J
    Acta Radiol; 2018 Jan; 59(1):81-88. PubMed ID: 28372493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of gadoxetate disodium: Results from the clinical phase II-III development program and postmarketing surveillance.
    Endrikat JS; Dohanish S; Balzer T; Breuer JA
    J Magn Reson Imaging; 2015 Sep; 42(3):634-43. PubMed ID: 25643844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients.
    Endrikat J; Kim SY; Sakaguchi T; Dohanish S; Breuer J
    Acta Radiol; 2016 Nov; 57(11):1326-1333. PubMed ID: 26048848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadobutrol for contrast-enhanced magnetic resonance imaging in elderly patients: review of the safety profile from clinical trial, post-marketing surveillance, and pharmacovigilance data.
    Endrikat J; Schwenke C; Prince MR
    Clin Radiol; 2015 Jul; 70(7):743-51. PubMed ID: 25933719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient Severe Motion Artifact Related to Gadoxetate Disodium-Enhanced Liver MRI: Frequency and Risk Evaluation at a German Institution.
    Well L; Rausch VH; Adam G; Henes FO; Bannas P
    Rofo; 2017 Jul; 189(7):651-660. PubMed ID: 28445909
    [No Abstract]   [Full Text] [Related]  

  • 6. Gadoxetate Disodium versus Gadoterate Meglumine: Quantitative Respiratory and Hemodynamic Metrics by Using Compressed-Sensing MRI.
    Glessgen CG; Moor M; Stieltjes B; Winkel DJ; Block TK; Merkle EM; Heye TJ; Boll DT
    Radiology; 2019 Nov; 293(2):317-326. PubMed ID: 31549944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadoxetate disodium-related event during image acquisition: a prospective multi-institutional study for better MR practice.
    Kromrey ML; Hori M; Goshima S; Kozaka K; Hyodo T; Nakamura Y; Nishie A; Tamada T; Shimizu T; Kanki A; Motosugi U
    Eur Radiol; 2020 Jan; 30(1):281-290. PubMed ID: 31338655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic steatosis: effect on hepatocyte enhancement with gadoxetate disodium-enhanced liver MR imaging.
    Onishi H; Theisen D; Dietrich O; Reiser MF; Zech CJ
    J Magn Reson Imaging; 2014 Jan; 39(1):42-50. PubMed ID: 24339365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study.
    Lauenstein T; Ramirez-Garrido F; Kim YH; Rha SE; Ricke J; Phongkitkarun S; Boettcher J; Gupta RT; Korpraphong P; Tanomkiat W; Furtner J; Liu PS; Henry M; Endrikat J
    Invest Radiol; 2015 Jun; 50(6):416-22. PubMed ID: 25756684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Gadoxetate Disodium on Arterial Phase Respiratory Waveforms Using a Quantitative Fast Fourier Transformation-Based Analysis.
    Davenport MS; Malyarenko DI; Pang Y; Hussain HK; Chenevert TL
    AJR Am J Roentgenol; 2017 Feb; 208(2):328-336. PubMed ID: 27929673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory-motion artefacts in liver MRI following injection of gadoxetate disodium and gadobenate dimeglumine: an intra-individual comparative study in cirrhotic patients.
    Furlan A; Close ON; Borhani AA; Wu YH; Heller MT
    Clin Radiol; 2017 Jan; 72(1):93.e1-93.e6. PubMed ID: 27633725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
    Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
    AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality.
    Davenport MS; Viglianti BL; Al-Hawary MM; Caoili EM; Kaza RK; Liu PS; Maturen KE; Chenevert TL; Hussain HK
    Radiology; 2013 Feb; 266(2):452-61. PubMed ID: 23192781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine.
    Davenport MS; Caoili EM; Kaza RK; Hussain HK
    Radiology; 2014 Jul; 272(1):123-31. PubMed ID: 24617733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-toxicity relationship of gadoxetate disodium and transient severe respiratory motion artifact.
    Davenport MS; Bashir MR; Pietryga JA; Weber JT; Khalatbari S; Hussain HK
    AJR Am J Roentgenol; 2014 Oct; 203(4):796-802. PubMed ID: 25055154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the gallbladder and cystic duct patency with gadoxetate disodium enhanced MR cholangiography: prospective comparison of patients with normal gallbladder function and acute cholecystitis.
    Yacoub JH; Yousuf A; Agrawal G; Thomas S; Appelbaum DE; Oto A
    Acta Radiol; 2015 Jul; 56(7):782-9. PubMed ID: 25009279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of gadoxetate disodium-enhanced MR cholangiography in chronic cholestatic biliary disease.
    Kühn JP; Spoerl M; Nassif A; Mester M; Weitschies W; Siegmund W; Hosten N; Mensel B
    Clin Radiol; 2014 Oct; 69(10):1027-33. PubMed ID: 24957855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
    Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
    AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary experience with intravenous gadoxetate disodium as a craniospinal MR contrast agent.
    McKinney AM; Gawande R; Pezeshk P; Truwit CL; Rykken JB
    Eur J Radiol; 2015 Dec; 84(12):2539-47. PubMed ID: 26456308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI assessment of biliary ductal obstruction: is there added value of T1-weighted gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR cholangiography?
    Reiner CS; Merkle EM; Bashir MR; Walle NL; Nazeer HK; Gupta RT
    AJR Am J Roentgenol; 2013 Jul; 201(1):W49-56. PubMed ID: 23789696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.